Ninepoint Partners LP Decreases Holdings in UnitedHealth Group Inc (UNH)

Ninepoint Partners LP trimmed its position in shares of UnitedHealth Group Inc (NYSE:UNH) by 16.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 70,252 shares of the healthcare conglomerate’s stock after selling 13,650 shares during the quarter. UnitedHealth Group makes up 3.2% of Ninepoint Partners LP’s portfolio, making the stock its 5th biggest holding. Ninepoint Partners LP’s holdings in UnitedHealth Group were worth $18,690,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Argent Trust Co increased its stake in UnitedHealth Group by 8.3% in the fourth quarter. Argent Trust Co now owns 13,911 shares of the healthcare conglomerate’s stock valued at $3,066,000 after purchasing an additional 1,061 shares during the last quarter. Principal Financial Group Inc. increased its stake in UnitedHealth Group by 6.5% in the first quarter. Principal Financial Group Inc. now owns 1,945,624 shares of the healthcare conglomerate’s stock valued at $416,364,000 after purchasing an additional 119,386 shares during the last quarter. Avalon Advisors LLC increased its stake in UnitedHealth Group by 12.4% in the first quarter. Avalon Advisors LLC now owns 198,237 shares of the healthcare conglomerate’s stock valued at $42,423,000 after purchasing an additional 21,838 shares during the last quarter. Neville Rodie & Shaw Inc. acquired a new position in UnitedHealth Group in the second quarter valued at $3,353,000. Finally, Cibc Bank USA acquired a new position in UnitedHealth Group in the second quarter valued at $1,863,000. Institutional investors own 85.44% of the company’s stock.

UNH has been the subject of several analyst reports. Citigroup lowered UnitedHealth Group from a “buy” rating to a “neutral” rating and set a $288.00 target price for the company. in a research note on Monday, September 10th. Raymond James upped their target price on UnitedHealth Group from $285.00 to $304.00 and gave the company a “strong-buy” rating in a research note on Monday, September 24th. Zacks Investment Research lowered UnitedHealth Group from a “buy” rating to a “hold” rating in a research note on Tuesday, September 18th. Morgan Stanley upped their target price on UnitedHealth Group from $278.00 to $305.00 and gave the company an “overweight” rating in a research note on Wednesday, September 5th. Finally, ValuEngine upgraded UnitedHealth Group from a “hold” rating to a “buy” rating in a research note on Tuesday, October 2nd. One research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $289.41.

Shares of NYSE:UNH opened at $260.93 on Friday. The stock has a market cap of $248.59 billion, a price-to-earnings ratio of 25.91, a PEG ratio of 1.49 and a beta of 0.73. The company has a quick ratio of 0.75, a current ratio of 0.69 and a debt-to-equity ratio of 0.61. UnitedHealth Group Inc has a 12 month low of $208.48 and a 12 month high of $272.81.

UnitedHealth Group (NYSE:UNH) last announced its quarterly earnings results on Tuesday, October 16th. The healthcare conglomerate reported $3.41 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.30 by $0.11. The company had revenue of $56.56 billion during the quarter, compared to analyst estimates of $56.34 billion. UnitedHealth Group had a return on equity of 23.62% and a net margin of 5.71%. The firm’s revenue was up 12.4% on a year-over-year basis. During the same period in the prior year, the firm posted $2.66 earnings per share. Research analysts predict that UnitedHealth Group Inc will post 12.81 EPS for the current fiscal year.

In other UnitedHealth Group news, Director William C. Ballard, Jr. sold 10,000 shares of the company’s stock in a transaction dated Wednesday, August 8th. The stock was sold at an average price of $258.83, for a total transaction of $2,588,300.00. Following the completion of the sale, the director now directly owns 77,172 shares in the company, valued at $19,974,428.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP D Ellen Wilson sold 15,393 shares of the company’s stock in a transaction dated Friday, August 24th. The stock was sold at an average price of $264.29, for a total value of $4,068,215.97. Following the sale, the executive vice president now owns 66,402 shares of the company’s stock, valued at $17,549,384.58. The disclosure for this sale can be found here. Insiders have sold 79,568 shares of company stock valued at $21,128,177 over the last 90 days. 0.87% of the stock is currently owned by insiders.

UnitedHealth Group Company Profile

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.

See Also: Leveraged Buyout (LBO) Explained

Want to see what other hedge funds are holding UNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UnitedHealth Group Inc (NYSE:UNH).

Institutional Ownership by Quarter for UnitedHealth Group (NYSE:UNH)

Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply